TY - JOUR AU - Sharma, Hema AU - Smith, Debra AU - Turner, Claire AU - Game, Laurence AU - Pichon, Bruno AU - Hope, Russell AU - Hill, Robert AU - Kearns, Angela AU - Sriskandan, Shiranee T1 - Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom T2 - Emerging Infectious Disease journal PY - 2018 VL - 24 IS - 2 SP - 258 SN - 1080-6059 AB - Staphylococcal toxic shock syndrome (TSS) was originally described in menstruating women and linked to TSS toxin 1 (TSST-1)–producing Staphylococcus aureus. Using UK national surveillance data, we ascertained clinical, molecular and superantigenic characteristics of TSS cases. Average annual TSS incidence was 0.07/100,000 population. Patients with nonmenstrual TSS were younger than those with menstrual TSS but had the same mortality rate. Children <16 years of age accounted for 39% of TSS cases, most caused by burns and skin and soft tissue infections. Nonmenstrual TSS is now more common than menstrual TSS in the UK, although both types are strongly associated with the tst+ clonal complex (CC) 30 methicillin-sensitive S. aureus lineage, which accounted for 49.4% of all TSS and produced more TSST-1 and superantigen bioactivity than did tst+ CC30 methicillin-resistant S. aureus strains. Better understanding of this MSSA lineage and infections in children could focus interventions to prevent TSS in the future. KW - staphylococcal toxic shock syndrome KW - bacteria KW - MRSA and other staphylococci KW - Staphylococcus aureus KW - TSST-1 KW - CC30 KW - ccpA KW - United Kingdom KW - antimicrobial resistance DO - 10.3201/eid2402.170606 UR - https://wwwnc.cdc.gov/eid/article/24/2/17-0606_article ER - End of Reference